Track topics on Twitter Track topics that are important to you
The addition of pertuzumab to standard trastuzumab therapy in patients with early HER2-positive breast cancer led to modest improvements and increased side effects in the APHINITY trial.
Medscape Medical News
Original Article: Is APHINITY the End of the Line for Trastuzumab Add-ons?NEXT ARTICLE
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...
Track and monitor developments in breast cancer research and commercial development. Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...